Long Noncoding RNA Interleukin 6 Antisense RNA 1 Promotes Inflammatory Effects in Lung Macrophages via Exosomes Through the S100A9/TLR4 Pathway in Chronic Obstructive Pulmonary Disease Progression

Abstract

This study investigates the role of interleukin 6 antisense RNA 1 (IL6-AS1), a highly expressed long noncoding RNA (lncRNA), in chronic obstructive pulmonary disease (COPD). An adeno-associated virus (AAV) was used to induce the expression of IL6-AS1 in mice, and they were exposed to cigarette smoke to establish a COPD model. IL6-AS1-overexpressing mice exposed to cigarette smoke demonstrated exacerbated COPD-like pathologies. Integrated with single-cell RNA sequencing analysis of COPD patients and pulmonary fibroblast–macrophage coculture system, our findings indicate that the upregulation of IL6-AS1 in fibroblasts enhances the interaction between the S100A9 protein and the AGER and TLR4 receptors on lung macrophages, thereby exacerbating pulmonary inflammation. The molecular mechanism likely involves exosome-mediated secretion, with IL6-AS1 binding to S100A9 protein. These findings suggest that IL6-AS1 may facilitate crosstalk between fibroblasts and macrophages, contributing to increased pulmonary inflammation, an effect that can be blocked by paquinimod. Mendelian randomization analysis further suggests a potential shared causal variant between IL6-AS1 and COPD risk. Taken together, this investigation provides valuable insights into the function of IL6-AS1 and its potential implications for the pathogenesis and therapeutic strategies in COPD.

Keywords

chronic obstructive pulmonary disease / lncRNA interleukin 6 antisense RNA 1 / S100A9 / macrophages / Mendelian randomization

References

[1] D. D. Sin, D. Doiron, A. Agusti, et al., “Air Pollution and COPD: GOLD 2023 Committee Report,” European Respiratory Journal 61, no. 5 (2023): 2202469.

[2] A. Agusti and J. C. Hogg, “Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease,” New England Journal of Medicine 381, no. 13 (2019): 1248-1256.

[3] S. Liu, Y. Zhou, S. Liu, et al., “Association Between Exposure to Ambient Particulate Matter and Chronic Obstructive Pulmonary Disease: Results From a Cross-sectional Study in China,” Thorax 72, no. 9 (2017): 788-795.

[4] A. N. Franciosi, D. Fraughen, T. P. Carroll, and N. G. McElvaney, “Alpha-1 Antitrypsin Deficiency: Clarifying the Role of the Putative Protective Threshold,” European Respiratory Journal 59, no. 2 (2022): 2101410.

[5] Y. Zhou, Y. Zou, X. Li, et al., “Lung Function and Incidence of Chronic Obstructive Pulmonary Disease After Improved Cooking Fuels and Kitchen Ventilation: A 9-year Prospective Cohort Study,” PLoS Medicine 11, no. 3 (2014): e1001621.

[6] W. Rao, S. Wang, M. Duleba, et al., “Regenerative Metaplastic Clones in COPD Lung Drive Inflammation and Fibrosis,” Cell 181, no. 4 (2020): 848-864. e818.

[7] M. Esteller, “Non-Coding RNAs in Human Disease,” Nature Reviews Genetics 12, no. 12 (2011): 861-874.

[8] J. S. Mattick, P. P. Amaral, P. Carninci, et al., “Long Non-coding RNAs: Definitions, Functions, Challenges and Recommendations,” Nature Reviews Molecular Cell Biology 24, no. 6 (2023): 430-447.

[9] R. W. Yao, Y. Wang, and L. L. Chen, “Cellular Functions of Long Noncoding RNAs,” Nature Cell Biology 21, no. 5 (2019): 542-551.

[10] E. G. De Smet, P. Mestdagh, J. Vandesompele, G. G. Brusselle, and K. R. Bracke, “Non-coding RNAs in the Pathogenesis of COPD,” Thorax 70, no. 8 (2015): 782-791.

[11] B. Ren, H. Su, C. Bao, H. Xu, and Y. Xiao, “Noncoding RNAs in Chronic Obstructive Pulmonary Disease: From Pathogenesis to Therapeutic Targets,” Noncoding RNA Res 9, no. 4 (2024): 1111-1119.

[12] E. Yi, J. Zhang, M. Zheng, et al., “Long Noncoding RNA IL6-AS1 Is Highly Expressed in Chronic Obstructive Pulmonary Disease and Is Associated With Interleukin 6 by Targeting miR-149-5p and Early B-cell Factor 1,” Clinical and Translational Medicine 11, no. 7 (2021): e479.

[13] E. Yi, B. Lin, Y. Zhang, et al., “Smad3-Mediated lncRNA HSALR1 Enhances the Non-Classic Signalling Pathway of TGF-beta1 in Human Bronchial Fibroblasts by Binding to HSP90AB1,” Clinical and Translational Medicine 13, no. 6 (2023): e1292.

[14] M. Zheng, W. Hong, and M. Gao, “Long Noncoding RNA COPDA1 Promotes Airway Smooth Muscle Cell Proliferation in Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory Cell and Molecular Biology 61, no. 5 (2019): 584-596.

[15] T. Vierbuchen, S. Agarwal, J. L. Johnson, et al., “The lncRNA LUCAT1 Is Elevated in Inflammatory Disease and Restrains Inflammation by Regulating the Splicing and Stability of NR4A2,” PNAS 120, no. 1 (2023): e2213715120.

[16] M. Laouedj, M. R. Tardif, L. Gil, et al., “S100A9 Induces Differentiation of Acute Myeloid Leukemia Cells Through TLR4,” Blood 129, no. 14 (2017): 1980-1990.

[17] W. Skronska-Wasek, S. Durlanik, H. Q. Le, et al., “The Antimicrobial Peptide S100A8/A9 Produced by Airway Epithelium Functions as a Potent and Direct Regulator of Macrophage Phenotype and Function,” European Respiratory Journal 59, no. 4 (2022): 2002732.

[18] C. Railwah, A. Lora, K. Zahid, et al., “Cigarette Smoke Induction of S100A9 Contributes to Chronic Obstructive Pulmonary Disease,” American Journal of Physiology. Lung Cellular and Molecular Physiology 319, no. 6 (2020): L1021-L1035.

[19] R. Y. Kim, K. P. Sunkara, K. R. Bracke, et al., “A microRNA-21-mediated SATB1/S100A9/NF-kappaB Axis Promotes Chronic Obstructive Pulmonary Disease Pathogenesis,” Science Translational Medicine 13, no. 621 (2021): eaav7223.

[20] C. A. Emdin, A. V. Khera, and S. Kathiresan, “Mendelian Randomization,” Jama 318, no. 19 (2017): 1925-1926.

[21] Q. Li, Y. Liu, X. Wang, et al., “The Influence of CLEC5A on Early Macrophage-Mediated Inflammation in COPD Progression,” Cellular and Molecular Life Sciences 81, no. 1 (2024): 330.

[22] J. D. Morrow, X. Zhou, T. Lao, et al., “Functional Interactors of Three Genome-wide Association Study Genes Are Differentially Expressed in Severe Chronic Obstructive Pulmonary Disease Lung Tissue,” Scientific Reports 7 (2017): 44232.

[23] S. Bhattacharya, S. Srisuma, D. L. Demeo, et al., “Molecular Biomarkers for Quantitative and Discrete COPD Phenotypes,” American Journal of Respiratory Cell and Molecular Biology 40, no. 3 (2009): 359-367.

[24] T. Cruz, A. Lopez-Giraldo, G. Noell, et al., “Smoking Impairs the Immunomodulatory Capacity of Lung-Resident Mesenchymal Stem Cells in Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory Cell and Molecular Biology 61, no. 5 (2019): 575-583.

[25] K. Steiling, M. van den Berge, K. Hijazi, et al., “A Dynamic Bronchial Airway Gene Expression Signature of Chronic Obstructive Pulmonary Disease and Lung Function Impairment,” American Journal of Respiratory and Critical Care Medicine 2013; 187(9): 933-942.

[26] M. Ramanathan, D. F. Porter, and P. A. Khavari, “Methods to Study RNA-Protein Interactions,” Nature Methods 16, no. 3 (2019): 225-234.

[27] M. Riva, E. Kallberg, P. Bjork, et al., “Induction of Nuclear Factor-kappaB Responses by the S100A9 Protein Is Toll-Like Receptor-4-Dependent,” Immunology 137, no. 2 (2012): 172-182.

[28] M. Rincon and C. G. Irvin, “Role of IL-6 in Asthma and Other Inflammatory Pulmonary Diseases,” Int J Biol Sci 8, no. 9 (2012): 1281-1290.

[29] F. Schleich, N. Bougard, C. Moermans, M. Sabbe, and R. Louis, “Cytokine-Targeted Therapies for Asthma and COPD,” Eur Respir Rev 32, no. 168 (2023): 220193.

[30] C. Wang, J. Zhou, J. Wang, et al., “Progress in the Mechanism and Targeted Drug Therapy for COPD,” Signal Transduct Target Ther 5, no. 1 (2020): 248.

[31] V. Allam, A. Faiz, M. Lam, et al., “RAGE and TLR4 Differentially Regulate Airway Hyperresponsiveness: Implications for COPD,” Allergy 76, no. 4 (2021): 1123-1135.

[32] N. Watanabe, Y. Fujita, J. Nakayama, et al., “Anomalous Epithelial Variations and Ectopic Inflammatory Response in Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory Cell and Molecular Biology 67, no. 6 (2022): 708-719.

[33] T. S. Adams, J. C. Schupp, S. Poli, et al., “Single-Cell RNA-seq Reveals Ectopic and Aberrant Lung-Resident Cell Populations in Idiopathic Pulmonary Fibrosis,” Science Advances 6, no. 28 (2020): eaba1983.

[34] L. J. Seys, F. M. Verhamme, A. Schinwald, et al., “Role of B Cell-Activating Factor in Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine 192, no. 6 (2015): 706-718.

[35] Y. Kono, T. Colley, M. To, et al., “Cigarette Smoke-Induced Impairment of Autophagy in Macrophages Increases Galectin-8 and Inflammation,” Scientific Reports 11, no. 1 (2021): 335.

[36] R. Shaykhiev, A. Krause, J. Salit, et al., “Smoking-dependent Reprogramming of Alveolar Macrophage Polarization: Implication for Pathogenesis of Chronic Obstructive Pulmonary Disease,” Journal of Immunology 183, no. 4 (2009): 2867-2883.

[37] S. L. O'Beirne, S. A. Kikkers, C. Oromendia, et al., “Alveolar Macrophage Immunometabolism and Lung Function Impairment in Smoking and Chronic Obstructive Pulmonary Disease,” American Journal of Respiratory and Critical Care Medicine 201, no. 6 (2020): 735-739.

[38] K. Van Crombruggen, T. Vogl, C. Perez-Novo, G. Holtappels, and C. Bachert, “Differential Release and Deposition of S100A8/A9 Proteins in Inflamed Upper Airway Tissue,” European Respiratory Journal 47, no. 1 (2016): 264-274.

[39] Z. He, Y. Zhong, P. Regmi, et al., “Exosomal Long Non-coding RNA TRPM2-AS Promotes Angiogenesis in Gallbladder Cancer Through Interacting With PABPC1 to Activate NOTCH1 Signaling Pathway,” Molecular Cancer 23, no. 1 (2024): 65.

[40] S. A. Christenson, B. M. Smith, M. Bafadhel, and N. Putcha, “Chronic Obstructive Pulmonary Disease,” Lancet 399, no. 10342 (2022): 2227-2242.

[41] I. A. Yang, C. R. Jenkins, and S. S. Salvi, “Chronic Obstructive Pulmonary Disease in Never-smokers: Risk Factors, Pathogenesis, and Implications for Prevention and Treatment,” Lancet Respir Med 10, no. 5 (2022): 497-511.

[42] A. Jukic, L. Bakiri, E. F. Wagner, H. Tilg, and T. E. Adolph, “Calprotectin: From Biomarker to Biological Function,” Gut 70, no. 10 (2021): 1978-1988.

[43] J. Roth, T. Vogl, C. Sorg, and C. Sunderkotter, “Phagocyte-specific S100 Proteins: A Novel Group of Proinflammatory Molecules,” Trends in Immunology 24, no. 4 (2003): 155-158.

[44] S. Wang, R. Song, Z. Wang, Z. Jing, S. Wang, and J. Ma, “S100A8/A9 in Inflammation,” Frontiers in Immunology 9 (2018): 1298.

[45] N. R. Scott, R. V. Swanson, N. Al-Hammadi, et al., “S100A8/A9 Regulates CD11b Expression and Neutrophil Recruitment During Chronic Tuberculosis,” Journal of Clinical Investigation 130, no. 6 (2020): 3098-3112.

[46] S. D. Pouwels, M. C. Nawijn, E. Bathoorn, et al., “Increased Serum Levels of LL37, HMGB1 and S100A9 During Exacerbation in COPD Patients,” European Respiratory Journal 45, no. 5 (2015): 1482-1485.

[47] D. Mei, W. S. D. Tan, Y. Tay, A. Mukhopadhyay, and W. S. F. Wong, “Therapeutic RNA Strategies for Chronic Obstructive Pulmonary Disease,” Trends in Pharmacological Sciences 41, no. 7 (2020): 475-486.

[48] X. Xu, H. Chen, X. Zhu, et al., “S100A9 promotes human Lung Fibroblast Cells Activation Through Receptor for Advanced Glycation End-product-mediated Extracellular-regulated Kinase 1/2, Mitogen-activated Protein-kinase and Nuclear Factor-kappaB-dependent Pathways,” Clinical and Experimental Immunology 173, no. 3 (2013): 523-535.

[49] E. A. Oczypok, T. N. Perkins, and T. D. Oury, “All the “RAGE” in Lung Disease: The Receptor for Advanced Glycation Endproducts (RAGE) Is a Major Mediator of Pulmonary Inflammatory Responses,” Paediatric Respiratory Reviews 23 (2017): 40-49.

[50] L. Lin, J. Li, Q. Song, W. Cheng, and P. Chen, “The Role of HMGB1/RAGE/TLR4 Signaling Pathways in Cigarette Smoke-induced Inflammation in Chronic Obstructive Pulmonary Disease,” Immunity, Inflammation and Disease 10, no. 11 (2022): e711.

[51] N. Gil and I. Ulitsky, “Regulation of Gene Expression by Cis-acting Long Non-coding RNAs,” Nature Reviews Genetics 21, no. 2 (2020): 102-117.

[52] X. Zhu, Y. Zhu, C. Ding, et al., “LncRNA H19 Regulates Macrophage Polarization and Promotes Freund's Complete Adjuvant-induced Arthritis by Upregulating KDM6A,” International Immunopharmacology 93 (2021): 107402.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.